Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

February 1, 2017
Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mike Ward, Informa Pharma Intelligence insight global director of content, how his company’s approach has potential to double brain cancer survival.
Previous Video
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets

Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking t...

Next Video
Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

An increased focus on the need to access and develop truly transformational medicines was a key theme in th...